[단독] Moder, vaccine, and GC Green Cross are commissioned to produce

Easy to distribute and distribute in Korea… Expected to serve as a global production base

[이미지출처=연합뉴스]

Exclusive[아시아경제 이광호 기자, 서소정 기자] GC Green Cross is commissioned to produce a new coronavirus infection (Corona 19) vaccine from Modena, a US pharmaceutical company. As a domestic company takes over the consignment production of the corona vaccine (CMO), it will not only serve as a global production base for the corona vaccine, but also will facilitate domestic distribution and distribution of the corona vaccine in the future.

On the 31st, a senior government official said, “I know that Modena has chosen GC Green Cross as a consignment production partner for the corona vaccine,” and said, “Agreement between Modena and GC Green Cross.” The official said, “The contract for securing a vaccine for 20 million people, which the government aims to sign with Modena within this year, and the contract for outsourced vaccine production are separate”. “The contract for 20 million people is currently underway by the Korea Centers for Disease Control and Prevention. “He explained.

President Moon Jae-in agreed to sign a memorandum of understanding (MOU) with the National Institute of Health and Infectious Diseases in a phone call with the CEO of Modena on the 28th to cooperate with the National Institute for Infectious Diseases and Pandemic development and vaccine material It also decided to strengthen cooperation for consignment production.

Bancell CEO said, “Even if a new virus emerges, cooperation with Korea (the period it takes to make a vaccine) will be much shorter than that of the development of the corona vaccine.” If we have the ability to consignment production, we can build a large-scale production capacity.”

As GC Green Cross decided to take over the consignment production of modders or vaccines, domestic companies will leap to a global production base for producing corona vaccines. Earlier, a domestic company, SK Bioscience, signed a contract for production with AstraZeneca in August and is currently supplying clinical trial products. The company has also signed a consignment development and production contract with NovaVax, another vaccine company, and the Korean government is currently negotiating with NovaVax to supply vaccines.

An official from the pharmaceutical industry said, “GC Green Cross has been attracting attention as a promising consignment manufacturer because it signed a contract with the Infectious Diseases Innovation Alliance (CEPI) to develop a corona 19 vaccine in the future.” “The existing vaccine production and distribution capabilities are solid and It seems that they have signed a contract with Modena while developing a blood device treatment system, etc.”

Reporter Lee Kwang-ho [email protected]
Reporter Seo So-jung [email protected]